This article is more than 5 years old. Information may no longer be current.
BLOG: Preeya Gupta enters the blogosphere
There’s a certified rock star in the room! Healio.com/OSN has welcomed one of academic ophthalmology’s brightest young stars to the blogosphere. Preeya Gupta has started a new blog here, providing her insights into the diagnosis and treatment of dry eye disease. For both of you who don’t know, Preeya is on the faculty of Duke University’s ophthalmology department, a member of Terry Kim’s crack cornea team. Her DED cred includes membership on the DEWS II panel that will soon report its updated DED protocols.
Aside from that, Preeya is pretty much everything we as practicing ophthalmologists could hope for in an academician who will become a leading voice going forward. In our DED world, we have been blessed to have a lineage of extraordinary women who have been trailblazers. Preeya and her contemporaries like Elizabeth Yeu, Katie Hatch, Priyanka Sood and Jennifer Loh are taking up the torch originally held by the still awe-inspiring Marguerite McDonald and passed along by luminaries such as Alice Epitropoulos, Neda Shamie, Laura Periman and others too numerous to mention.
Introducing Preeya here is kinda like Lou Reed welcoming Alicia Keys to the stage. You know, funky-looking old dude who writes weird stuff introduces the brilliant young voice of what’s new.
The DED space is barely recognizable to anyone who’s been at it as long as I have, and there’s a real need for more voices weighing in on the whats, whys and hows of dry eye. I’ve gotten to know Preeya pretty well over the last couple of years, and it’s going to be fun to hear her take on DED. Unlike Lou Reed who sadly won’t be writing any more songs, I plan to continue my “walk on the wild side” of DED. Our stage has become big enough for all kinds of music.
Welcome aboard, Preeya! Fasten your seatbelt.
Disclosure: White reports he is a consultant for Bausch + Lomb, Allergan, Shire and Eyemaginations; is on the speakers board for Bausch + Lomb, Allergan and Shire; and has a financial interest in TearScience.